<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/the-medicines-nasdaqmdco-trading-up-19-7.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T12:56:52+00:00"/>
    <meta property="og:title" content="The Medicines (NASDAQ:MDCO) Trading Up 19.7%"/>
    <meta property="og:description" content="The Medicines Company (NASDAQ:MDCO)’s share price was up 19.7% during mid-day trading on Tuesday . The stock traded as high as $59.00 and last traded at $70.23, approximately 475,055 shares were traded during mid-day trading. A decline of 70% from the average daily volume of 1,564,413 shares. The stock had previously closed at $58.65. Several […]"/>
  </head>
  <body>
    <article>
      <h1>The Medicines (NASDAQ:MDCO) Trading Up 19.7%</h1>
      <address><time datetime="2019-11-21T12:56:52+00:00">21 Nov 2019, 12:56</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/the-medicines-compan-logo.jpg"/>
      </figure>
      <p>The Medicines Company (NASDAQ:MDCO)’s share price was up 19.7% during mid-day trading on Tuesday . The stock traded as high as $59.00 and last traded at $70.23, approximately 475,055 shares were traded during mid-day trading. A decline of 70% from the average daily volume of 1,564,413 shares. The stock had previously closed at $58.65.</p>
      <p>Several research analysts have issued reports on MDCO shares. Leerink Swann restated a “buy” rating on shares of The Medicines in a research report on Tuesday, September 3rd. BidaskClub upgraded shares of The Medicines from a “hold” rating to a “buy” rating in a research report on Thursday. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=MDCO">ValuEngine</a> lowered shares of The Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America restated a “buy” rating and issued a $51.00 price target on shares of The Medicines in a research report on Monday, August 26th. Finally, Chardan Capital restated a “buy” rating and issued a $100.00 price target on shares of The Medicines in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $72.77.</p>
      <p>The business’s 50 day moving average is $54.34 and its 200 day moving average is $41.87. The company has a debt-to-equity ratio of 21.45, a quick ratio of 0.77 and a current ratio of 0.77. The stock has a market cap of $4.14 billion, a price-to-earnings ratio of -24.08 and a beta of 0.90.</p>
      <p>The Medicines (NASDAQ:MDCO) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.12). During the same period in the previous year, the business earned ($0.70) EPS. Research analysts expect that The Medicines Company will post -3.4 earnings per share for the current year.</p>
      <p>A number of institutional investors have recently bought and sold shares of MDCO. Mason Street Advisors LLC boosted its stake in shares of The Medicines by 7.6% during the 3rd quarter. Mason Street Advisors LLC now owns 25,058 shares of the company’s stock valued at $1,253,000 after buying an additional 1,774 shares during the period. Grimes &amp; Company Inc. acquired a new stake in shares of The Medicines during the 3rd quarter valued at $250,000. Tower Research Capital LLC TRC boosted its stake in shares of The Medicines by 1,156.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,186 shares of the company’s stock valued at $109,000 after buying an additional 2,012 shares during the period. Fayerweather Charles bought a new position in shares of The Medicines during the 3rd quarter valued at $237,000. Finally, SG Americas Securities LLC raised its holdings in shares of The Medicines by 179.2% during the 3rd quarter. SG Americas Securities LLC now owns 10,178 shares of the company’s stock valued at $509,000 after purchasing an additional 6,532 shares in the last quarter.</p>
      <p><b>About The Medicines</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/MDCO/">NASDAQ:MDCO</a>)</p>
      <p>The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/market-data/gap-down-stocks/">Why are gap-down stocks important?</a></p>
    </article>
  </body>
</html>